Prognostic significance of molecular staging study of sentinel lymph nodes by reverse transcriptase-polymerase chain reaction for tyrosinase in melanoma patients

Annals of Surgical Oncology

Volumn 13, Issue 7, 2006, Pages 910-918

  Mangas, Cristina ^a   Hilari, Josep M ^a   Paradelo, Cristina ^a   Rex, Jordi ^a   Fernández Figueras, Maria Teresa ^a   Fraile, Manel ^a   Alastrue, Antoni ^a   Ferrándiz, Carlos ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Melanoma; Molecular staging; Reverse transcriptase polymer chain reaction; Sentinel lymph node; Tyrosinase

Indexed keywords

BETA ACTIN; EOSIN; HEMATOXYLIN; MONOCLONAL ANTIBODY HMB 45; MONOPHENOL MONOOXYGENASE;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; EVALUATION; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPHOSCINTIGRAPHY; MAJOR CLINICAL STUDY; MALE; MELANOMA; PROBABILITY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; SPAIN;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; MONOPHENOL MONOOXYGENASE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 33745237195     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/ASO.2006.12.010     Document Type: Article

References (34)

1. Balch CM. Cutaneous melanoma: prognosis and treatment results worldwide. Semin Surg Oncol 1992; 8:400-14.
2. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127:392-9.
3. McMasters KM, Reintgen DS, Ross MI, et al. Sentinel lymph node biopsy for melanoma: controversy despite widespread agreement. J Clin Oncol 2001; 19:2851-5.
4. Cochran AJ, Wen DR, Morton DL. Occult tumor cells in the lymph nodes of patients with pathological stage I malignant melanoma. An immunohistological study. Am J Surg Pathol 1988; 12:612-8.
5. Yu LL, Flotte TJ, Tanabe KK, et al. Detection of microscopic melanoma metastases in sentinel lymph nodes. Cancer 1999; 86:617-27.
6. Gershenwald JE, Colome MI, Lee JE, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 1998; 16:2253-60.
7. Shivers SC, Wang X, Li W, et al. Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA 1998; 280:1410-5.
8. Wang X, Heller R, Van Voorhis N, et al. Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma. Ann Surg 1994; 220:768-74.
9. Blaheta HJ, Schittek B, Breuninger H, et al. Lymph node micrometastases of cutaneous melanoma: increased sensitivity of molecular diagnosis in comparison to immunohistochemistry. Int J Cancer 1998; 79:318-23.
10. Li W, Stall A, Shivers SC, et al. Clinical relevance of molecular staging for melanoma: comparison of RT-PCR and immunohistochemistry staining in sentinel lymph nodes of patients with melanoma. Ann Surg 2000; 231:795-803.
11. Hoon DS, Wang Y, Dale PS, et al. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol 1995; 13:2109-16.
12. Sarantou T, Chi DD, Garrison DA, et al. Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer Res 1997; 57:1371-6.
13. Hatta N, Takata M, Takehara K, Ohara K. Polymerase chain reaction and immunohistochemistry frequently detect occult melanoma cells in regional lymph nodes of melanoma patients. J Clin Pathol 1998; 51:597-601.
14. Kuo CT, Hoon DS, Takeuchi H, et al. Prediction of disease outcome in melanoma patients by molecular analysis of paraffin-embedded sentinel lymph nodes. J Clin Oncol 2003; 21:3566-72.
15. Balch CM, Buzaid AC, Soong S-J, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635-48.
16. Paradelo C, Fraile M, Ferrandiz C, Alastrue A, Bigata X. Lymphoscintigraphy in the study of lymphatic drainage patterns in patients with melanoma. Med Clin (Barc) 1999; 113:281-4.
17. Rex J, Paradelo C, Mangas C, et al. Single-institutional experience in the management of patients with clinical stage I and II cutaneous melanoma. Results of the sentinel lymph node biopsy in 240 cases. Dermatol Surg 2005; 31:1385-93..
18. Smith B, Selby P, Southgate J, Pittman K, Bradley C, Blair GE. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 1991; 338:1227-9.
19. Reintgen D, Balch CM, Kirkwood J, Ross M. Recent advances in the care of the patient with malignant melanoma. Ann Surg 1997; 225:1-14.
20. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000; 18:2444-58.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-81.
22. Wagner JD, Corbett L, Park HM, et al. Sentinel lymph node biopsy for melanoma: experience with 234 consecutive procedures. Plast Reconstr Surg 2000; 105:1956-66.
23. Albertini JJ, Cruse CW, Rapaport D, et al. Intraoperative radio-lympho-scintigraphy improves sentinel lymph node identification for patients with melanoma. Ann Surg 1996; 223:217-24.
24. Ribuffo D, Gardilone A, Vonella M, et al. Prognostic significance of reverse transcriptase-polymerase chain reaction-negative sentinel nodes in malignant melanoma. Ann Surg Oncol 2003; 10:396-402.
25. Bostick PJ, Morton DL, Turner RR, et al. Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J Clin Oncol 1999; 17:3238-44.
26. Takeuchi H, Morton DL, Kuo C, et al. Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. J Clin Oncol 2004; 22:2671-80.
27. Blaheta HJ, Schittek B, Breuninger H, et al. Detection of melanoma micrometastasis in sentinel nodes by reverse transcription-polymerase chain reaction correlates with tumor thickness and is predictive of micrometastatic disease in the lymph node basin. Am J Surg Pathol 1999; 23:822-8.
28. Goydos JS, Patel KN, Shih WJ, et al. Patterns of recurrence in patients with melanoma and histologically negative but RT-PCR-positive sentinel lymph nodes. J Am Coll Surg 2003; 196:196-204.
29. Kammula US, Ghossein R, Bhattacharya S, Coit DG. Serial follow-up and the prognostic significance of reverse transcriptase-polymerase chain reaction-staged sentinel lymph nodes from melanoma patients. J Clin Oncol 2004; 22:3989-96.
30. Bautista NC, Cohen S, Anders KH. Benign melanocytic nevus cells in axillary lymph nodes. A prospective incidence and immunohistochemical study with literature review. Am J Clin Pathol 1994; 102:102-8.
31. Johansson M, Arstrand K, Hakansson A, Lindholm C, Kagedal B. Quantitative analysis of tyrosinase and tyrosinase-related protein-2 mRNA from melanoma cells in blood by real-time polymerase chain reaction. Melanoma Res 2000; 10:213-22.
32. Davids V, Kidson SH, Hanekom GS. Melanoma patient staging: histopathological versus molecular evaluation of the sentinel node. Melanoma Res 2003; 13:313-24.
33. McMasters KM, Noyes RD, Reintgen DS. Lessons learned from the Sunbelt Melanoma Trial. J Surg Oncol 2004; 86:212-23.
34. Cayuela A, Rodriguez-Dominguez S, Lapetra-Peralta J, Conejo-Mir JS. Has mortality from malignant melanoma stopped rising in Spain? Analysis of trends between 1975 and 2001. Br J Dermatol 2005; 152:997-1000.